Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is LAMIVUDINE USP, with a corresponding US DMF Number 17750.
Remarkably, this DMF maintains an Active status since its submission on October 08, 2004, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 28, 2013, and payment made on August 20, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II